BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giese-kim N, Wu M, Dehghan M, Sceats LA, Park K. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases. Am J Gastroenterol 2020;115:1698-706. [DOI: 10.14309/ajg.0000000000000750] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jacob J, Aintabi D, DeJonckheere M, Cohen-Mekelburg SA, Allen JI, Irani DN, Fendrick AM, Waljee AK, Higgins PDR, Berinstein JA. Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic. Res Social Adm Pharm 2022:S1551-7411(22)00202-9. [PMID: 35871146 DOI: 10.1016/j.sapharm.2022.06.009] [Reference Citation Analysis]
2 Rowan C, Ungaro R, Mehandru S, Colombel JF. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opin Pharmacother 2022. [PMID: 35503955 DOI: 10.1080/14656566.2022.2071605] [Reference Citation Analysis]
3 Tan G, Huang C, Chen J, Chen B, Shi Y, Zhi F. An IRF1-dependent pathway of TNFα-induced shedding in intestinal epithelial cells. J Crohns Colitis 2021:jjab134. [PMID: 34309645 DOI: 10.1093/ecco-jcc/jjab134] [Cited by in F6Publishing: 4] [Reference Citation Analysis]